Table 1.
Correlation of CDX2 and MUC2 expression with clinico-pathological parameters and classifications.
| Parameter | n | CDX2 positive cases (%) | MUC2 positive cases (%) |
| Age (yr) | |||
| ≤60 yr | 87 | 48 (55.2) | 14 (16.1) |
| ＞60 yr | 103 | 61 (59.2) | 27 (26.2) |
| P | 0.57 | 0.09 | |
| Gender | |||
| Female | 90 | 57 (63.3) | 21 (23.3) |
| Male | 100 | 52 (52) | 20 (20) |
| P | 0.11 | 0.58 | |
| WHO classification | |||
| Mucinous | 4 | 3 (75) | 4 (100) |
| Signet-ring cell | 85 | 49 (57.6) | 13 (15.3) |
| Tubular/papillary | 80 | 47 (58.8) | 20 (25) |
| Undifferentiated | 21 | 10 (47.6) | 4 (19) |
| P | 0.71 | 0.0007 | |
| Lauren classification | |||
| Diffuse | 105 | 61 (58.1) | 19 (18.1) |
| Intestinal | 70 | 40 (57.1) | 18 (25.7) |
| Unclassified/mixed | 15 | 8 (53.3) | 4 (26.7) |
| P | 0.94 | 0.43 | |
| Goseki classification | |||
| Type I | 54 | 30 (55.6) | 14 (25.9) |
| Type II | 22 | 16 (72.7) | 6 (27.3) |
| Type III | 20 | 9 (45) | 3 (15) |
| Type IV | 94 | 54 (57.4) | 18 (19.1) |
| P | 0.33 | 0.60 | |
| pTNM stages | |||
| I | 53 | 29 (54.7) | 7 (13.2) |
| II | 58 | 41 (70.7) | 18 (31) |
| III | 54 | 27 (50) | 10 (18.5) |
| IV | 25 | 12 (48) | 6 (24) |
| P | 0.09 | 0.13 | |
| pT stages | |||
| pT1 | 33 | 16 (48.5) | 4 (12.1) |
| pT2 | 112 | 69 (61.6) | 28 (25) |
| pT3 | 32 | 18 (56.3) | 6 (18.8) |
| pT4 | 13 | 6 (45.2) | 3 (23.1) |
| P | 0.46 | 0.44 | |
| pN stages | |||
| pN0 | 52 | 31 (59.6) | 8 (15.4) |
| pN1 | 76 | 48 (63.2) | 21 (27.6) |
| pN2 | 52 | 25 (48.1) | 9 (17.3) |
| pN3 | 10 | 5 (50) | 3 (30) |
| P | 0.36 | 0.28 |